Protein kinase C-δ-mediated recycling of active KIT in colon cancer

Misun Park1, Won Kyu Kim, Meiying Song

  • 1Authors' Affiliations: Departments of Pathology and Brain Korea 21 Projects for Medical Science, Yonsei University College of Medicine; and Department of Biological Sciences, Creative Research Initiative Center for Chromatin Dynamics, Seoul National University, Seoul, South Korea.

Abstract

Insights

Wild-type KIT (WT-KIT) activation by stem cell factor (SCF) drives colon cancer progression. Protein kinase C-delta (PKC-δ) recycles WT-KIT, sustaining signaling and correlating with poor patient survival.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Receptor tyrosine kinase (RTK) aberrant signaling is crucial in colorectal cancer (CRC) tumorigenesis and targeted therapy.
  • Wild-type KIT (WT-KIT), an RTK activated by stem cell factor (SCF), is overexpressed in some colon cancers, but its role in pathogenesis is unclear.

Purpose of the Study:

  • To investigate the conditions and functional roles of WT-KIT activation in colon cancer development.
  • To elucidate the molecular mechanisms regulating WT-KIT stability and signaling in response to SCF.

Main Methods:

  • Characterization of KIT expression in colorectal cancers using immunoblotting and immunohistochemistry.
  • Analysis of biological alterations following KIT-SCF binding, with and without protein kinase C (PKC) activation.
  • Investigation of the role of PKC-δ in WT-KIT regulation and signaling.

Main Results:

  • WT-KIT activation by SCF triggers downstream AKT and ERK signaling pathways in colon cancer cells.
  • Prolonged SCF stimulation leads to lysosomal degradation of WT-KIT, which is rescued by PKC activation.
  • Activated PKC-δ mediates WT-KIT recycling, sustaining downstream signaling.
  • Co-expression of WT-KIT and activated PKC-δ in a subset of CRCs correlates with poor patient survival (P = 0.004).

Conclusions:

  • PKC-δ-mediated recycling of WT-KIT sustains downstream signaling after KIT-SCF binding.
  • This sustained KIT activation may drive tumor progression in a subset of colon cancers.
  • Targeting KIT presents a potential therapeutic strategy for these patients.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...